| Accession |
PRJCA016205 |
| Title |
An open-label, multicenter, phase II study of the treatment of previously untreated advanced or metastatic gastric or gastroesophageal junction cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
An open-label, multicenter, phase II study of sequential treatment with the PD-1 antibody SHR-1210 plus capecitabine and oxaliplatin or SHR-1210 plus apatinib mesylate in patients with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer. |
| Sample scope |
Multiisolate |
| Release date |
2023-04-12 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-12 |
